Introduction
High levels of corticotropin releasing factor immunoactivity (CRFi), a hypothalamic releasing hormone which stimulates pituitary ß-endorphin (ß-EP) and ACTH secretion, are present in the plasma of women during the second half of pregnancy [2, 7] . This is in distinction to the undetectable or extremely small amounts of the hypothalamic releasing factor which have been reported in the peripheral plasma of healthy non-pregnant adults [9] . The CRFi measurable in the plasma of non-pregnant adults appears to be of hypothalamic origin [9] while there are several lines of evidence to support a placental source for the CRFi measured in the plasma during pregnancy. A substance similar in molecular weight to CRF has been extracted from term human placentas which causes the release of ACTH and ß-EP from rat anterior pituitary cells in culture [8] . In addition, we have found a highly significant correlation between simultaneously obtained maternal and fetal CRFi levels at delivery as well as a higher CRFi concentration in the umbilical vein compared to the umbilical artery, again suggesting a placental source for both maternal and fetal CRFi [2] . These results, together with the disappearance of CRFi from maternal plasma within 24 hours after delivery [2, 7] , provide strong evidence that the placenta secretes CRFi into the maternal and fetal circulations during gestation.
Little is known about the regulation of this placental CRFi during pregnancy. We have previously reported that umbilical cord plasma ACTH and ß-EP are inversely correlated with pU2 and pH [11] while no significant relationship was observed between fetal plasma CRFi and pH [2] suggesting that in the fetus, hypoxia and acidosis are not stimuli for increased CRFi release by the placenta. In the present study, we have examined the effects of an acute dose of betamethasone, a long-acting corticosteroid, on maternal plasma CRFi as well as ACTH and cortisol levels. Several studies have supported the concept that glucocorticoids exert their negative feedback effect at both a pituitary and a hypothalamic level [4, 6, 10] . We have undertaken the present study to investigate whether glucocorticoids similarly suppress the release of CRFi by the placenta during pregnancy.
Methods
Eleven pregnant women at 28 -32 weeks gestation were hospitalized for premature labor and treated with betamethasone to induce fetal lung maturation. Five of the 11 patients received tocolytic agents as well. Baseline 8 A.M. plasma samples were drawn for CRFi, ACTH and cortisol measurements. Betamethasone 12 mgs was given intramuscularly to these patients at 11 P. M. and CRFi, ACTH and cortisol were again measured at 8 A. M. the following morning.
CRFi was extracted from 1 ml plasma with Sep-pak C-18 cartridges (Waters Associates, Milford, MA) and measured by RIA using antiserum to human CRF raised in this laboratory. Assay sensitivity was lOpg/tube and 44 pg/ml when 1 ml of plasma was extracted. ACTH was extracted from 2 ml plasma with talc tablets as described previously [3] and measured by RIA using synthetic human ACTH and the West antiserum supplied by the National Pituitary Agency. Cortisol was measured by competitive protein binding.
Samples were collected in ice-chilled glass tubes containing EDTA (for CRF determinations) or heparin (for ACTH and cortisol measurements) and were immediately centrifuged at 4°C. Plasma was either extracted for assay immediately or frozen at -20 °C and thawed once for assay within 2 weeks.
Results
Before the administration of betamethasone, the mean (+ SEM) plasma cortisol concentration was 21.9 ±3 ug/dl, mean plasma ACTH concentration was 45.4 + 6.4 pg/ml and mean plasma CRFi was 180 ±65 pg/ml (figure 1). Mean maternal plasma ACTH and cortisol levels were significantly depressed after betamethasone administration while plasma CRFi remained unchanged. The mean maternal postbetamethasone ACTH concentration fell to 25.4 ± 5.2 pg/ml (p < 0.05) and the mean cortisol level fell to 9.5 ± 1.2 ug/dl (p < 0.01).
Mean maternal plasma CRFi concentration after betamethasone was 214 + 69 pg/ml with a range of 48 -835 pg/ml.
There was no significant correlation between maternal plasma CRFi and ACTH or cortisol concentrations. As expected there was a highly significant correlation between maternal plasma ACTH and cortisol levels (figure 2).
• 
Discussion
In this study we report that the administration of betamethasone to pregnant women does not inhibit the placental secretion of CRFi into maternal plasma. Thus, the acute regulation of placental CRFi appears to be distinct from that of hypothalamic CRF. Several investigators have shown that glucocorticoids have inhibitory effects on both pituitary ACTH and hypothalamic CRF accounting for the suppression of cortisol secretion. ROBERTS et al. [6] have shown that the production of the proopiomelanocortin derived peptides, such as ACTH, is under direct negative control by glucocorticoids. An effect of glucocorticoids on CRF was demonstrated by SUDA et al. who reported that the acute administration of dexamethasone to rats caused a significant decrease in the hypothalamic CRF content [10] while in a more recent study, JINGAMI et al. reported that dexamethasone administered to adrenalectomized rats lowered the messenger RNA for the CRF precursor in the hypothalamus [4] . Our finding that glucocorticoids to not inhibit placental CRF release only reflects the effects of a single dose of betamethasone. The effect of chronic treatment with glucocorticoids remains unknown.
Summary
Corticotropin releasing factor immunoactivity (CRFi) has been identified in the plasma of women in the second half of gestation. There are several lines of evidence supporting a placental source for this hormone. Regulation of placental CRFi is poorly understood. In this study, the effect of a long-acting glucorticoid on the release of placental CRFi was investigated. Eleven women in the third trimester of pregnancy had plasma samples measured for CRFi, ACTH and cortisol
We also report a lack of correlation between CRFi and either ACTH or cortisol in maternal plasma during pregnancy. However, although the biological activity and physiologic significance of this CRFi is unknown, this lack of correlation does not exclude the possibility that placental CRFi influences ACTH and cortisol secretion during pregnancy. It is possible that placental CRFi is playing a permissive role in causing ACTH release in response to hypothalamic CRF.
The highly significant correlation between maternal ACTH and cortisol levels, with slightly elevated cortisol levels, is in agreement with the results of previous reports [1, 5] .
In summary, we report that high levels of CRFi are present in maternal plasma in the final weeks of gestation and have previously shown that CRFi becomes detectable at 18 weeks of gestation, increases progressively with advancing gestational age, and disappears from maternal plasma within 24 hours after delivery [2] . This placental CRFi is not suppressed by betamethasone, while maternal plasma ACTH and cortisol levels are lowered by the administration of this long-acting glucocorticoid. These results suggest that the acute regulation of placental CRFi is distinct from the regulation of hypothalamic CRF.
before and after receiving 12 mg betamethasone. There was a significant decrease in ACTH (p < 0.05) and cortisol levels (p < 0.01) but no change in CRFi. It is concluded that the secretion of CRFi by the placenta is not inhibited by the administration of betamethasone while maternal levels of cortisol and ACTH are lowered. These results suggest that the acute regulation of placental CRFi is distinct from the regulation of hypothalamic CRF.
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Zusammenfassung Einfluß von Betamethason auf die maternalen Plasmaspiegel von Kortikotropin-Releasing-Faktor, ACTH und Kortisol während der Schwangerschaft
In der zweiten Schwangerschaftshälfte konnte im Plasma schwangerer Frauen ein Kortikotropin-Releasing-Faktor mit Immunaktivität (CRFi) nachgewiesen werden.
Es gibt mehrere Hinweise auf die Plazenta als Syntheseort. Über welche Regulationsmechanismen dieses Hormon gebildet wird, ist nicht bekannt. In der vorliegenden Studie wurde der Einfluß eines langwirkenden Glukokortikoids auf die Freisetzung von plazentarem CRFi untersucht. 
